Moderna (NASDAQ:MRNA) Stock Rating Lowered by Oppenheimer

Oppenheimer lowered shares of Moderna (NASDAQ:MRNA) from an outperform rating to a market perform rating in a research note issued to investors on Friday, MarketBeat Ratings reports.

A number of other research analysts have also recently issued reports on MRNA. Evercore ISI reaffirmed an in-line rating and issued a $120.00 price target on shares of Moderna in a report on Thursday, June 27th. Barclays cut their price target on Moderna from $168.00 to $155.00 and set an overweight rating for the company in a report on Friday, August 2nd. JPMorgan Chase & Co. cut their price target on Moderna from $96.00 to $88.00 and set a neutral rating for the company in a report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised Moderna from a sell rating to a hold rating and cut their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Finally, William Blair restated a market perform rating on shares of Moderna in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Hold and an average target price of $103.93.

Moderna Stock Up 1.3 %

Shares of NASDAQ:MRNA opened at $69.17 on Friday. Moderna has a 52 week low of $62.55 and a 52 week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The company’s fifty day moving average is $94.12 and its 200-day moving average is $111.72. The company has a market capitalization of $26.51 billion, a PE ratio of -4.41 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same quarter in the previous year, the company earned ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. Equities research analysts predict that Moderna will post -9.52 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total value of $1,908,300.00. Following the completion of the sale, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total value of $1,908,300.00. Following the completion of the sale, the director now directly owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock worth $11,167,312 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several institutional investors have recently bought and sold shares of MRNA. Ashton Thomas Private Wealth LLC acquired a new position in Moderna during the second quarter worth $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna during the fourth quarter worth $27,000. Cedar Wealth Management LLC raised its position in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in Moderna during the first quarter worth $32,000. Finally, Family Firm Inc. bought a new stake in Moderna during the second quarter worth $33,000. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.